TCM
BPMC

Tang Capital Management’s Blueprint Medicines BPMC Stock Holding History

Tang Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-50,000
Closed -$4.61M – 108
2023
Q4 		$4.61M Buy
+50,000
New +$3.24M 0.43% 61
2023
Q1 		– Sell
-40,000
Closed -$1.75M – 110
2022
Q4 		$1.75M Hold
40,000
– – 0.25% 65
2022
Q3 		$2.64M Buy
+40,000
New +$2.57M 0.32% 64

Other funds holding BPMC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tang Capital Management's BPMC Position: Q1 2024 in Review

Tang Capital Management sold out of Blueprint Medicines (BPMC) in Q1 2024, closing a stake of 50,000 shares — an estimated $4.61M sold.

Tang Capital Management first reported a position in BPMC in Q3 2022 and held it in 3 quarters. The position peaked at $4.61M in Q4 2023. 283 funds tracked by Wall St. Rank hold BPMC as of Q1 2024.

  • Tang Capital Management reported no remaining Blueprint Medicines position as of Q1 2024 after selling out during the quarter.
  • Tang Capital Management sold 50,000 Blueprint Medicines shares in Q1 2024, an estimated $4.61M.
  • Tang Capital Management first reported a position in Blueprint Medicines in Q3 2022 and held it in 3 quarters.
  • Tang Capital Management's Blueprint Medicines position peaked at $4.61M in Q4 2023.
  • 283 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2024.

Based on Tang Capital Management's 13F filing for Q1 2024, filed 15 May 2024.